Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 6/2004

01-05-2004 | Current Opinion

Intranasal Cold-Adapted Influenza Virus Vaccine Combined with Inactivated Influenza Virus Vaccines

An Extra Boost for the Elderly?

Authors: Paul V. Targonski, Dr Gregory A. Poland

Published in: Drugs & Aging | Issue 6/2004

Login to get access

Abstract

Although influenza vaccine delivery strategies have improved coverage rates to unprecedented levels nationally among persons aged 65 years and older, influenza remains one of the greatest vaccine-preventable threats to public health among elderly in the US. A new, intranasal live attenuated influenza vaccine (LAIV) was recently approved by the US FDA for use in persons aged 5–49 years, which excludes the elderly population. Limitations of immune response to inactivated influenza vaccine (IAIV) and effectiveness of current influenza vaccination strategies among the elderly suggest that a combined approach using LAIV and/or the IAIV in various permutations might benefit this group. We explore characteristics of the LAIV, data regarding its utility in protecting against influenza in the elderly, and challenges and opportunities regarding potential combined inactivated/live attenuated vaccination strategies for the elderly. Although LAIV appears to hold promise either alone or in combination with IAIV, large well conducted randomised trials are necessary to define further the role of LAIV in preventing influenza morbidity and mortality among the elderly. We also suggest that innovative vaccine coverage strategies designed to optimise prevention and control of influenza and minimise viral transmission in the community must accompany, in parallel, the acquisition of clinical trials data to best combat morbidity and mortality from influenza.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002; 51: 1–31
2.
Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87: 1944–50PubMedCrossRef
3.
Simonsen L, Fukuda K, Schonberger LB, et al. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000; 181: 831–7PubMedCrossRef
4.
Williams GO. Vaccines in older patients: combating the risk of mortality. Geriatrics 1980; 35: 55–64PubMed
5.
US Bureau of the Census. Age 2000: census 2000 brief. Washington, DC: US Government Printing Office, 2001
6.
US Bureau of the Census. Projections of the total resident population by 5-year age groups, and sex with special age categories: middle series, 1999–2075. Washington, DC: US Bureau of the Census; 2000 Jan. Report no.: NP-T3-A
7.
Day JC. Population projections of the United States by age, sex, race and Hispanic origin: 1995 to 2050. Washington, DC: US Bureau of the Census; 1996 Feb. Current population report no.: P25-1130
8.
Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661–5PubMedCrossRef
9.
Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778–84PubMedCrossRef
10.
Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1994; 270: 1956–61CrossRef
11.
Hak E, Nordin J, Wei F, et al. Influence of high risk medical conditions on the effectiveness of influenza vaccination among elderly members of three large managed care organizations. Clin Infect Dis 2002; 35: 370–7PubMedCrossRef
12.
Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998; 158: 1769–76PubMedCrossRef
13.
Nordin J, Mullooly J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001; 184: 665–70PubMedCrossRef
14.
Barker WH, Mullooly JP. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244: 2547–9PubMedCrossRef
15.
Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518–27PubMed
16.
17.
Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, editor. Fields virology. New York: Raven Press, 1998: 1397–447
18.
Armstrong SJ, Dimmock NJ. Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited. J Virol 1992; 66: 3823–32PubMed
19.
Couch RB, Kasel JA, Six HR, et al. Immunological reactions and resistance to infection with influenza virus. In: Stuart-Harris C, Potter C, editors. Molecular virology epidemiology of influenza. London: Academic Press, 1984: 119–53
20.
McMichael A. Cytotoxic T lymphocytes specific for influenza virus. Curr Top Microbiol Immunol 1994; 189: 75–91PubMedCrossRef
21.
Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24: 157–60PubMed
22.
Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23: 66–72PubMed
23.
Couch RB. Immunization for the prevention of influenza. In: Root RK, Warren KS, Giffiss JM, et al., editors. Contemporary issues in infectious diseases: immunization. New York: Churchill Livingstone, 1989: 37–45
24.
Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP) prevention and control of influenza. MMWR Morb Mortal Wkly Rep 1984; 33: 253–66
25.
Waldman RH, Stone J, Bergman K, et al. Secretory antibody following oral influenza immunization. Am J Med Sci 1986; 262: 367–71CrossRef
26.
Clements ML, Betts RF, Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984; I: 705–8CrossRef
27.
Gorse GJ, Otto EE, Powers DC, et al. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J Infect Dis 1996; 173: 285–90PubMedCrossRef
28.
Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15: 962–7PubMedCrossRef
29.
30.
Massab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 1999; 9: 237–44CrossRef
31.
Mills J, Chanock V, Chanock RM. Temperature-sensitive mutants of influenza virus (I): behavior in tissue culture and in experimental animals. J Infect Dis 1971; 123: 145–57PubMedCrossRef
32.
Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133–7PubMedCrossRef
33.
Gorse GJ, Belshe RB, Munn NJ. Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. J Clin Microbiol 1988; 26(5): 911–8PubMed
34.
Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136: 168–75PubMedCrossRef
35.
Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza-virus vaccine in children. N Engl J Med 1998; 338: 1405–12PubMedCrossRef
36.
Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282: 137–44PubMedCrossRef
37.
Murphy BR. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults, and elderly adults. Infect Dis Clin Pract 1993; 2: 174–81CrossRef
38.
Beyer WEP, Palache AM, de Jong JC, et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: a meta-analysis. Vaccine 2002; 20: 1340–53PubMedCrossRef
39.
Treanor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117: 625–33PubMed
40.
Edwards KM, Dupont WD, Westrich MK, et al. A randomized controlled trial of cold-adapted and inactivated vaccine for the prevention of influenza A disease. J Infect Dis 1994; 169: 68–79PubMedCrossRef
41.
Boyce TG, Poland GA. Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: a review. Biomed Pharmacother 2000; 54: 210–8PubMedCrossRef
42.
King Jr JC, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001; 20: 1124–31PubMedCrossRef
43.
Vesikari T. Randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live, attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending day care [abstract]. 41st Annual Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001 Dec 16–19; Chicago
44.
Wright PF, Okabe N, McKee Jr KT, et al. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982; 146: 71–9PubMedCrossRef
45.
Pfleiderer M, Lower J, Kurth R. Cold-attenuated live influenza vaccines, a risk-benefit assessment. Vaccine 2001; 20: 886–94PubMedCrossRef
46.
Harper SA, Fukuda K, Cox NJ, et al. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2003; 52: 1–8
47.
Ferry BJ, Evered MG, Morrison El. Difference protection rates in various groups of volunteers given subunit influenza vaccine in 1976. J Infect Dis 1979; 39: 237–41CrossRef
48.
Govaert TME, Sprenger MJW, Dinant GJ, et al. Immune response to influenza vaccination of elderly people: a randomized double-blind plecebo-controlled trial. Vaccine 1994; 12: 1185–9PubMedCrossRef
49.
Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70: 767–77CrossRef
50.
D’Alessio DJ, Cox Jr PM, Dick EC. Failure of inactivated influenza vaccine to protect an aged population. JAMA 1969; 210: 485–9PubMedCrossRef
51.
Goronzy JJ, Fulbright JW, Crowson CS, et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75: 12182–7PubMedCrossRef
52.
Fujihashi K, Koga T, McGhee JR. Mucosal vaccination and immune responses in the elderly. Vaccine 2000; 18: 1675–80PubMedCrossRef
53.
Beyer WEP, Palache AM, Baljet M, et al. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7: 385–94PubMedCrossRef
54.
Keren G, Segev S, Morag A, et al. Failure of influenza vaccination in the aged. J Med Virol 1988; 25: 85–9PubMedCrossRef
55.
Palmer DF, Dowdle WR, Coleman MT, et al. Haemagglutination-inhibition test. In: US Department of Health and Welfare, editor. Advanced laboratory techniques for influenza diagnosis: procedural Guide. Atlanta (GA): US Department of Health and Welfare, 1975: 25–62
56.
Bernstein E, Kaye D, Abrutyn E, et al. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999; 17: 82–94PubMedCrossRef
57.
Muszkat M, Yehuda AB, Schein MH, et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol 2000; 61: 100–6PubMedCrossRef
58.
Hoskins TW, Davies JR, Smith AJ, et al. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ’s Hospital. Lancet 1979; I: 33–5CrossRef
59.
Beyer WEP, de Bruijn IA, Palache AM, et al. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 1999; 159: 182–8PubMedCrossRef
60.
Ahmed AH, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989–90 epidemic. Lancet 1995; 346: 591–5PubMedCrossRef
61.
Betts RF, O’Brien D, Menegus M, et al. A comparison of the protective benefit of influenza vaccine in reducing hospitalization of patients infected with influenza A or influenza B [abstract]. Clin Infect Dis 1993; 17: 573
62.
Gravenstein S, Drinka P, Duthie EH, et al. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am Geriatr Soc 1994; 42: 245–51PubMed
63.
Waldman RH, Bergmann KC, Stone J, et al. Age-dependent antibody response in mice and humans following oral influenza immunization. J Clin Immunol 1987; 7: 327–32PubMedCrossRef
64.
Fulk RV, Fedson DS, Huber MA, et al. Antibody responses in serum and nasal secretions according to age of recipient and method of administration of A2-Hong Kong-68 inactivated influenza virus vaccine. J Immunol 1970; 104: 8–13PubMed
65.
Powers DC, Sears SD, Murphy BR, et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989; 27: 2666–71PubMed
66.
Powers DC, Fries LF, Murphy BR, et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991; 29: 498–505PubMed
67.
Powers DC, Murphy BR, Fries LF, et al. Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc 1992; 40: 163–7PubMed
68.
Treanor JJ, Betts RF. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects. Vaccine 1998; 16: 1756–60PubMedCrossRef
69.
Gorse GJ, Belshe RB, Munn NJ. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 1991; 100: 977–84PubMedCrossRef
70.
Gorse GJ, Otto EE, Daughaday CC, et al. Influenza virus vaccination of patients with chronic lung disease. Chest 1997; 112: 1221–33PubMedCrossRef
71.
Couch RB. Summary of medical literature: review of effectiveness of inactivated influenza virus vaccine. In: Office of Technology Assessment, editor. Cost-effectiveness of influenza vaccination. Washington, DC: Office of Technology Assessment, 1981: 43–5
72.
Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995; 172: 389–94PubMedCrossRef
73.
Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol 2001; 154: 155–60PubMedCrossRef
74.
Taylor JL, Dwyer DM, Coffman T, et al. Nursing home outbreak of influenza A (H3N2): evaluation of vaccine efficacy and influenza case definitions. Infect Control Hosp Epidemiol 1992; 13: 93–7PubMedCrossRef
75.
Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987; 77: 712–6PubMedCrossRef
76.
Ailing DW, Blackwelder WC, Stuart-Harris CH. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol 1981; 113: 30–43
77.
Feery BJ, Evered MG, Morrison EI. Antibody responses to influenza virus subunit vaccine in the aged. Med J Aust 1976; 1: 540–2PubMed
78.
Googins JA. A/Victoria outbreak in Portland nursing homes, January 1976. Atlanta (GA): Centers for Disease Control and Prevention Surveillance Report, 1977 Jul. Report no.: 91
79.
Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38–44PubMedCrossRef
80.
Patriarca PA. A randomized controlled trial of influenza vaccine in the elderly: scientific scrutiny and ethical responsibility. JAMA 1994; 272: 1700–1PubMedCrossRef
81.
82.
83.
Gruber WC, Belshe RB, King JC, et al. Evaluation of live attenuated influenza vaccines in children 6–18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 1996; 173: 1313–9PubMedCrossRef
84.
Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947–52PubMed
85.
Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2003; 52: 1–34
86.
87.
Poland GA. If you could halve the mortality rate, would you do it? Clin Infect Dis 2002; 35: 378–80PubMedCrossRef
88.
Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged ≥65 years: United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50: 532–7
89.
US Department of Health and Human Services. Healthy people 2010 immunization goals. Washington, DC: US Government Printing Office, 2000
90.
Bratzler DW, Houck PM, Jiang H, et al. Failure to vaccinate Medicare inpatients. Arch Intern Med 2002; 162: 2349–56PubMedCrossRef
91.
van Essen GA, Kuyvenhoven MM, de Melker RA. Why do healthy elderly people fail to comply with influenza vaccination? Age Ageing 1997; 26: 275–9PubMedCrossRef
92.
93.
Glezen WP, Decker M, Joseph SW, et al. Acute respiratory disease associated with influenza epidemics in Houston, 1981–1983. J Infect Dis 1987; 155: 1119–26PubMedCrossRef
94.
Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating school children against influenza. N Engl J Med 2001; 344: 889–96PubMedCrossRef
95.
Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175: 1–6PubMedCrossRef
96.
Walker FJ, Singleton JA, Strikas RA. Influenza vaccination of health care workers in the United States, 1989–1997 [abstract]. Infect Control Hosp Epidemiol 2000; 21: 113
97.
Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137: 225–31PubMed
98.
Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA 1983; 249: 3189–95PubMedCrossRef
99.
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889–93PubMedCrossRef
100.
Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 1999; 281: 908–13PubMedCrossRef
101.
Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284: 1655–63PubMedCrossRef
102.
Demicheli V, Jefferson T, Rivetti D, et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957–1030PubMedCrossRef
Metadata
Title
Intranasal Cold-Adapted Influenza Virus Vaccine Combined with Inactivated Influenza Virus Vaccines
An Extra Boost for the Elderly?
Authors
Paul V. Targonski
Dr Gregory A. Poland
Publication date
01-05-2004
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 6/2004
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200421060-00001

Other articles of this Issue 6/2004

Drugs & Aging 6/2004 Go to the issue

Original Research Article

Risk of Antipsychotic Drug Use in Patients with Alzheimer’s Disease Treated with Rivastigmine

Review Article

Effect of Antihypertensive Agents on Quality of Life in the Elderly

Original Research Article

Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease

Leading Article

Depression in Aging Men
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits